• Explore /
  • Poster
  • / Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.

Overall responses with coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer: A single center, single arm trial.

Abstract Poster

Authors

null

Jonathan Alexander Chatzkel

Moffitt Cancer Center, Tampa, FL

Jonathan Alexander Chatzkel , Jennifer Swank , Steven Ludlow , Kristina Lombardi , Cortlin Croft , Yesenia Artigas , Yazmin Rodriguez , Tina Terraciano , Sarah Hart , Jennifer Rembisz , Elaine Johnson , Michael J. Schell , Jiqiang Yao , Jingsong Zhang , Mayer N. Fishman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02964078

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 657)

DOI

10.1200/JCO.2019.37.7_suppl.657

Abstract #

657

Poster Bd #

J10

Abstract Disclosures

Similar Posters

First Author: Alexander Starodub

First Author: Jie Yu

First Author: Ahmad A. Tarhini

First Author: Rosa Nadal